References
- Medina MT, Moncada SS. Hydroxychloroquine/chloroquine as a treatment choice or prophylaxis for Covid-19 at the primary care level in developing countries: a Primum non Nocere dilemma. J Neurol Sci. 2020;415:116972. doi:10.1016/j.jns.2020.116972
- Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — final report. N Engl J Med. 2020;383(19):1813–1826. doi:10.1056/NEJMoa2007764
- Oldenburg CE, Doan T. Azithromycin for severe COVID-19. Lancet. 2020;396(10256):936–937. doi:10.1016/S0140-6736(20)31863-8
- Furtado RHM, Berwanger O, Fonseca HA, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020;396(10256):959–967. doi:10.1016/S0140-6736(20)31862-6
- Fiolet T, Guihur A, Rebeaud ME, Mulot M, Peiffer-Smadja N, Mahamat-Saleh Y. Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(1):19–27. doi:10.1016/j.cmi.2020.08.022
- Gonzalez-Zorn B. Antibiotic use in the COVID-19 crisis in Spain. Clin Microbiol Infect. 2021;27(4):646–647. doi:10.1016/j.cmi.2020.09.055
- Antimicrobial resistance. European centre for disease prevention and control; 12 de marzo de 2021. Disponible en: https://www.ecdc.europa.eu/en/antimicrobial-resistance. Accessed November 7, 2021.
- Coronavirus disease (COVID-19): Herd immunity, lockdowns and COVID-19 [Internet]. World Health Organization; 2020 [ citado 26 de enero de 2021]. Disponible en: https://www.who.int/news-room/q-A-detail/herd-immunity-lockdowns-and-covid-19. Accessed November 7, 2021.
- State official newsletter. Royal Decree 463/2020, of March 14, which declares the state of alarm for the management of the health crisis situation caused by COVID-19. [Internet]. 67. Sec:25390–25400. Disponible en: https://www.boe.es/boe/dias/2020/03/14/pdfs/BOE-A-2020-3692.pdf. Accessed November 7, 2021.
- State official newsletter. Order SND / 422/2020, of May 19, which regulates the conditions for the mandatory use of a mask during the health crisis caused by COVID-19. [Internet]; May 20, 2020:33600–33602. Disponible en: https://www.boe.es/buscar/doc.php?id=BOE-A-2020-5142. Accessed November 7, 2021.
- COVID-19 early detection, surveillance and control strategy [Internet]. Ministerio de Sanidad. Gobierno de España; 2020 [ citado 25 de enero de 2021]. Disponible en: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/documentos/COVID19_Estrategia_vigilancia_y_control_e_indicadores.pdf. Accessed November 7, 2021.
- Romero L, Pao LZ, Clark H, et al. Health center testing for SARS-CoV-2 during the COVID-19 pandemic — United States, June 5–October 2, 2020. Morb Mortal Wkly Rep. 2021;69(50):1895–1901. doi:10.15585/mmwr.mm6950a3
- Wolters F, van de Bovenkamp J, van den Bosch B, et al. Multi-center evaluation of cepheid xpert® xpress SARS-CoV-2 point-of-care test during the SARS-CoV-2 pandemic. J Clin Virol. 2020;128:104426. doi:10.1016/j.jcv.2020.104426
- de Wolff T, Pflüger D, Rehme M, Heuer J, Bittner M-I. Evaluation of pool-based testing approaches to enable population-wide screening for COVID-19. PLoS One. 2021;15:e0243692. doi:10.1371/journal.pone.0243692
- Gagliotti C, Buttazzi R, Ricchizzi E, Di Mario S, Tedeschi S, Moro ML. Community use of antibiotics during the COVID-19 lockdown. Infect Dis. 2021;53(2):142–144. doi:10.1080/23744235.2020.1834139
- Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index. World Health Organization [Internet]; 2020 [ citado 28 de enero de 2021]. Disponible en: https://www.whocc.no/atc_ddd_index/?code=J01&showdescription=no. Accessed November 7, 2021.
- State official newsletter. Royal Decree-Law 16/2012, of April 20, on urgent measures to guarantee the sustainability of the National Health System and improve the quality and safety of its services. BOE núm. 98; April 24, 2012.
- Statistics National Institute. Population Figures. Provisional as of July 1, 2020; 25 de marzo de 2021. Disponible en: https://www.ine.es/dyngs/INEbase/es/operacion.htm?c=Estadistica_C&cid=1254736176951&menu=ultiDatos&idp=1254735572981. Accessed November 7, 2021.
- Budgets of the Autonomous Communities: Health. Expansión; 25 de marzo de 2021. Disponible en: https://datosmacro.expansion.com/estado/presupuestos/espana-comunidades-autonomas?sc=PR-G-F-31. Accessed November 7, 2021.
- Rioja Health. Basic Health Zones; 25 de marzo de 2021. Disponible en: https://www.riojasalud.es/ciudadanos/informacion/libre-eleccion-sanitaria/atencion-primaria.
- Organización Mundial de la Salud. Defined daily dose (DDD). Definition and general considerations [Internet]; [citado 22 de octubre de 2021]. Disponible en: https://www.who.int/tools/atc-ddd-toolkit/about-ddd. Accessed November 7, 2021.
- Pediatricians attend up to 14 years of age and, for now, they do not want more; [ citado 22 de octubre de 2021]. Disponible en: https://www.redaccionmedica.com/secciones/pediatria/los-pediatras-atienden-hasta-los-14-anos-y-de-momento-no-quieren-mas-3026. Accessed November 7, 2021.
- IBM Corp. IBM SPSS Statistics for Windows. Armonk, NY: IBM Corp; 2016.
- Burgos Rincón F, Martínez Llorens J, Cordovilla Pérez R. Impact of the COVID-19 pandemic on lung function laboratories: considerations for “Today” and the “Day After”. Arch Bronconeumol. 2020;56(10):611–612. doi:10.1016/j.arbres.2020.07.001
- Grabowski DC, Mor V. Nursing home care in crisis in the wake of COVID-19. JAMA. 2020;324(1):23–24. doi:10.1001/jama.2020.8524
- National Plan against Antibiotic Resistance (PRAN). EAAD 2020 Conference: Antibiotic consumption in Spain recovers its pre-pandemic downward trend; 18 de noviembre de 2020. Disponible en: https://resistenciaantibioticos.es/en/node/578. Accessed November 7, 2021.
- Rojas García P, Antoñanzas Villar F. Effects of economic and health policies on the consumption of antibiotics in a Spanish region. Expert Rev Pharmacoecon Outcomes Res. 2020;20(4):379–386. doi:10.1080/14737167.2019.1647105
- Antoñanzas Villar F, Rodríguez-Ibeas R, Juárez-Castelló CA, Lorente Antoñanzas MR. Impact of the Royal Decree-Law 16/2012 on the Number of Prescriptions and Pharmaceutical Expenditures. Rev Esp Salud Pública. 2014;88(2):233–249. doi:10.4321/S1135-57272014000200006
- Puig-Junoy J, Rodríguez-Feijóo S, López-Valcárcel BG. Impact of the Pharmaceutical Copayment Reform on the Use of Antidiabetics, Antithrombotics and Drugs for Chronic Airflow Obstructions. Spain. Rev Esp Salud Pública. 2017;90:15.
- Ministry of Health. Prescription billing information; 26 de marzo de 2021. Disponible en: https://www.mscbs.gob.es/profesionales/farmacia/datos/diciembre2020.htm. Accessed November 7, 2021.
- Ministries of Health. Pharmaceutical Benefit in the National Health System Annual Report of the National Health System 2018; 2020. Disponible en: https://www.mscbs.gob.es/estadEstudios/estadisticas/sisInfSanSNS/tablasEstadisticas/InfAnualSNS2018/Cap.7_Farmacia.pdf. Accessed November 7, 2021.